secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2023-07-17T23:59:59+00:00
Accession:  0001193125-23-187579
Event type: other_material
Sentiment:  positive
Materiality: 0.88
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen's ACU193 Phase 1 meets endpoints; plaque reduction up to 25%, low ARIA-E rate
--------------------------------------------------------------------------------

- 60 mg/kg Q4W cohort showed 25% mean amyloid plaque reduction at day 63; 25 mg/kg Q2W showed 20% at day 70.
- Overall ARIA-E rate 10.4% (5/48); symptomatic ARIA-E 2.1% (1/48); no drug-related serious adverse events.
- Statistically significant dose-proportional PK and near-maximal target engagement of toxic AβOs in CSF.
- Monthly dosing supported by pharmacokinetic and CSF data; company plans FDA interaction in Q4 2023.
- INTERCEPT-AD enrolled 60 early-AD participants; results to be submitted for peer-reviewed publication.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000119312523187579/0001193125-23-187579-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000119312523187579/d518971d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-187579

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer